Market Research Logo

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

Stem cell therapy for diabetes and related conditions: An insight

The stem cell therapy for diabetes and related conditions pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for diabetes and related conditions treatment. Most of the pipeline therapeutics are in early stage of development, a long-lasting and less frequent dose can impact overall diabetes market.

In 2015, the American Diabetes Association (ADA) estimated that the annual total cost of diabetic patients is $223.5 billion in the US alone. The global annual cost is estimated at $465 billion and is expected to reach $510 billion a year by 2030.

Covered in this report

The report covers the present scenario and the growth prospects of the stem cell therapy for diabetes and related conditions. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

  • Athersys
  • Mesoblast
  • Caladrius Biosciences
  • Sanofi
  • Novo Nordisk
  • Key questions answered in this report
    • How will the market evolve during the forecast period?
    • What are the major parameters impacting the market?
    • What are the key market trends?
    • What are the challenges to market growth?
    • Who are the key companies in this market space?


    Press Release

    Technavio Announces the Publication of its Research Report - Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

    Technavio recognizes the following companies in the stem cell therapy for diabetes and related conditions: Athersys, Mesoblast, Caladrius Biosciences, Sanofi, and Novo Nordisk.

    The “Stem cell therapy for diabetes and related conditions - A pipeline analysis report, 2017” provides comprehensive insights about pipeline molecules in this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under stem cell therapy for diabetes and related conditions.

    This report provides information on the therapeutic development based on the stem cell therapy for diabetes and related conditions dealing with all the pipeline drugs; comparative analysis at various stages covering Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also highlights the discontinued and dormant products.

    Diabetes is a metabolic disorder. It is a chronic condition associated with high sugar (glucose) level in the blood. Insulin, a hormone produced by the pancreas of the body, lowers the glucose level in the blood. Any defect in insulin secretion, or its action, or both, causes abnormal blood glucose level. Diabetes can be classified into two types, type 1 (insulin-dependent diabetes mellitus or juvenile onset) and type 2 (non-insulin-dependent diabetes mellitus, or adult-onset diabetes). In type 1 diabetes, the body does not produce insulin. In type 2 diabetes, which is the more common type (90%-95%), the body does not make or use insulin well. It can affect all people, regardless of age and sex.

    Companies Mentioned

    Athersys, Mesoblast, Caladrius Biosciences, Sanofi, and Novo Nordisk.

    • Executive summary
    • Scope of the report
    • Research Methodology
    • Stem cell therapy for diabetes and related conditions: An insight
      • Introduction
    • Major regulatory authorities
      • US
        • Table Drug approval process by US FDA
      • Europe
      • Japan
      • Australia
      • China
    • Pipeline landscape
      • Table Active pipeline molecules by vendors
      • Table Pipeline landscape
    • Comparative analysis
      • Table Pipeline molecules by numbers
      • Table Pipeline molecules by percentage
      • Mid-stage molecules (Phase II)
        • Table Overview: ALLO-ASC-DFU
        • Table Clinical trials description of ALLO-ASC-DFU
        • Table Overview: MPC-300-IV
        • Table Clinical trials description of MPC-300-IV
        • Table Overview: CLBS 03
        • Table Clinical trials description of CLBS 03
        • Table Overview: PDA-002
        • Table Clinical trials description of PDA-002
      • Early-stage molecules (Phase I/II)
        • Table Overview: PEC-Encap (VC-01)
        • Table Clinical trials description of PEC-Encap (VC-01)
        • Table Overview: PEC-Direct (VC-02)
        • Table Clinical trials description of PEC-Direct (VC-02)
      • Pre-clinical stage molecules
        • Table Overview: NSI-566
        • Table Overview: VC-03
        • Table Overview: VC-04
        • Table Overview: MultiStem
        • Table Overview: Research Program
        • Table Overview: Diabetes beta cell therapy
        • Table Overview: Cell therapy for diabetes
        • Table Overview: Cell therapy for diabetes
        • Table Overview: Cell therapy for diabetes
        • Table Overview: ProTrans
      • Inactive and discontinued molecules
        • Table Inactive molecules
        • Table Discontinued molecule
    • Indication analysis
      • Table Analysis by indication
      • Table Overview of indications
    • Therapeutic assessment by therapy type
      • Table Assessment of pipeline products by therapy
    • Therapeutic assessment by RoA
      • Table Assessment of pipeline products by RoA
    • Key companies
      • Active companies: Category and parameters
        • Table Active companies: Category and parameters 2017
        • Table Segmentation of companies
        • Table Overview: Anterogen 2017
        • Table Overview: Athersys 2017
        • Table Overview: Caladrius Biosciences 2017
        • Table Overview: Cellular Therapeutics 2017
        • Table Overview: Islexa 2017
        • Table Overview: Kadimastem 2017
        • Table Overview: Mesoblast 2017
        • Table Overview: Neuralstem 2017
        • Table Overview: NextCell Pharma 2017
        • Table Overview: Novo Nordisk 2017
        • Table Overview: Orgenesis 2017
        • Table Overview: Sanofi 2017
        • Table Overview: ViaCyte 2017
    • Appendix
      • List of abbreviations
    • Explore Technavio

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report